Excellent Antiviral Activity Research Articles

Anti-Herpes Simplex Virus Type-1 Activity of Kyllinga nemoralis Roots Aqueous Extract

Human Herpesvirus 1 known as herpes simplex virus type 1 (HSV-1) is belonged to the Herpesviridae family, Alphaherpesvirinae subfamily, and Simplexvirus genus. Kyllinga nemoralis, known as whitehead spike sedge, white kyllinga, white globose spike, or poverty grass, is a monocotyledonous flowering graminoid similar to grasses and rushes. Acyclovir (ACV) did not eradicate HSV-1 infection as the drug only focuses on inhibiting the production of new viral genomes by interfering with viral DNA synthesis. This study aimed to identify the cytotoxic concentration (CC50) of K. nemoralis roots aqueous extract and evaluate its antiviral activities against HSV-1. 
 
 Cytotoxicity assay involved the incubation of Vero cells with 10 concentrations of extract ranging between 0.002 mg/mL and 1.000 mg/mL. MTT solution was added and absorbance was measured at 540 nm [1]. The CC50 of extract was determined from the graph of cell viability (%) against extract concentrations. Antiviral assays of post-treatment, pre-treatment and virucidal tests determined the mode of antiviral activity. The 50 % effective concentration (EC50) of extract was derived from the graph of plaque inhibition (%) against concentrations. Selectivity index (SI) was evaluated as the ratio of CC50 to EC50 [2]. 
 
 
 Post-treatment assay: Cells were inoculated with HSV-1 for 2 hours. Extract with (2% DMEM and 1% MCS) was added into cells and incubated for 48 hours. 
 Pre-treatment assay: Cells were treated with extract in 5% DMEM for 24 hours and inoculated with HSV-1 for 1 hour 30 minutes. Then, cells were overlaid with (2% DMEM and 1% MCS) and incubated for 48 hours. 
 Virucidal assay: HSV-1 was incubated with extract for 30 minutes. Then, virus-extract suspension was inoculated into cells and overlaid with 2% DMEM and 1% MCS for 48 hours. 
 
 
 After 48 hours incubation, cells were stained with crystal violet solution and incubated at room temperature for 30 minutes. The plaques were counted and percentage of plaque inhibition (%) was calculated. 
 The CC50 revealed aqueous extract concentration was able to kill at 50% of cell population. Post-treatment assay showed that 0.062 mg/mL of the extract inhibited intracellular viral replication. Pre-treatment study indicated that 0.02 mg/mL of extract produced protective effects towards cells. Finally, virucidal assay demonstrated that 0.222 mg/mL of extract initiated extracellular interaction with virus in inhibiting infection [3] as shown in Table 1. 
 The cytotoxicity study showed that CC50, 0.72 mg/mL was toxic on cells. Therefore, lower concentrations between 0.016 mg/mL to 0.5 mg/mL, that were least or non-toxic to the cells were utilized in the subsequent antiviral screenings [4]. The extract showed good inhibition of intracellular virus replication with an EC50 of 0.062 mg/mL and SI more than 10 which is 11.61. Similarly, in pre-treatment investigation, the extract produced excellent antiviral activity with an EC50 of 0.02 mg/mL and corresponding SI of 36.00. This finding highlight that the extract is most effective when administered as pre-treatment. Antiviral activity exhibited by roots extract probably results from the inhibition of host cell glycoprotein receptors or due to prevention of binding between HSV-1 virions and host cells [5]. Virucidal assay revealed a weak extracellular interaction between HSV-1 and extract. It was supported by the low SI, 3.24 as shown in Figure 1.1. The finding suggests that 30 minutes of virus-extract exposure could be insufficient for roots extract to show an effective inhibition of virus [2]. In conclusion, the present study revealed that K. nemoralis roots aqueous extract inhibits in-vitro productive HSV-1 infection through three different modes that are effective prevention of intracellular viral replication, excellent interaction with host cell surface to inhibit HSV-1 infection and moderate direct destruction the virus particles.

Indole-Containing Natural Products 2019-2022: Isolations, Reappraisals, Syntheses, and Biological Activities.

Indole alkaloids represent a large subset of natural products, with more than 4100 known compounds. The majority of these alkaloids are biologically active, with some exhibiting excellent antitumor, antibacterial, antiviral, antifungal, and antiplasmodial activities. Consequently, the natural products of this class have attracted considerable attention as potential leads for novel therapeutics and are routinely isolated, characterized, and profiled to gauge their biological potential. However, data on indole alkaloids, their various structures, and bioactivities are complex due to their diverse sources, such as plants, fungi, bacteria, sponges, tunicates, and bryozoans; thus, isolation methods produce an incredible trove of information. The situation is exacerbated when synthetic derivatives, as well as their structures, bioactivities, and synthetic schemes, are considered. Thus, to make such data comprehensive and inform researchers about the current field's state, this review summarizes recent reports on novel indole alkaloids. It deals with the isolation and characterization of 250 novel indole alkaloids, a reappraisal of previously reported compounds, and total syntheses of indole alkaloids. In addition, several syntheses and semi-syntheses of indole-containing derivatives and their bioactivities are reported between January 2019 and July 2022.

Disulfiram Inclusion Complexes - A Nebulization Approach to Fight COVID-19

Disulfiram (DS) has an excellent anti-viral activity; however, its low water-solubility and first-pass metabolism are limiting its clinical applications. Cyclodextrins (CDs) have been used as solubility enhancers and carriers of DS proposed for inhalation to treat SARS-CoV-19. Two types of CDs (hydroxypropyl β-cyclodextrin and sulfobutyl ether β-cyclodextrin) were used to form inclusion complexes with DS, and drug solubility was assessed using spectrophotometric analytical method. Formulations were freeze-dried and characterized using DSC, TGA and FTIR. Nebulization technique was used to assess the potential for generating aerosols. All inclusion complexes are proved to be suitable for inhalation, therefore, potentially effective therapy for further investigation against SARS-CoV-19 is shown. 

In vitro Virucidal Activity of Silver Nanoparticles against H1N1 Influenza A Virus and Herpes Simplex Virus-1

Silver nanoparticles (AgNPs) have provided a broad spectrum of antiviral activity against some types of enveloped and non-enveloped viruses. Silver nanoparticles are currently the most widely commercialized nanomaterials. In recent times, viral infections are emerging as one of the most common diseases with high mortality in the human population. The present study investigates the antiviral efficacy of the silver nanoparticles synthesized by the green method against HSV-1 and H1N1 influenza viruses. Characterization studies revealed that the silver nanoparticles showed an average particle size of 47 nm with a surface plasmon resonance peak at 426 nm. Silver nanoparticles exhibited 50% cytotoxicity in Vero cells at 197 µg/mL concentration, and 50% Inhibitory concentration (IC50) against HSV-1 was observed at 19.6 μg/mL. Silver nanoparticles demonstrated > 1 log reduction in H1N1 influenza A virus at 17 µg/mL. These findings indicate that silver nanoparticles possess excellent antiviral activity, which can be suitably used in various formulations to eradicate the spread of viral infections.

Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.

The continuous spread of SARS-CoV-2 calls for more direct-acting antiviral agents to combat the highly infectious variants. The main protease (Mpro) is an promising target for anti-SARS-CoV-2 drug design. Here, we report the discovery of potent non-covalent non-peptide Mpro inhibitors featuring a 1,2,4-trisubstituted piperazine scaffold. We systematically modified the non-covalent hit MCULE-5948770040 by structure-based rational design combined with multi-site binding and privileged structure assembly strategies. The optimized compound GC-14 inhibits Mpro with high potency (IC50 = 0.40 μM) and displays excellent antiviral activity (EC50 = 1.1 μM), being more potent than Remdesivir. Notably, GC-14 exhibits low cytotoxicity (CC50 > 100 μM) and excellent target selectivity for SARS-CoV-2 Mpro (IC50 > 50 μM for cathepsins B, F, K, L, and caspase 3). X-ray co-crystal structures prove that the inhibitors occupy multiple subpockets by critical non-covalent interactions. These studies may provide a basis for developing a more efficient and safer therapy for COVID-19.

RNA G-quadruplex formed in SARS-CoV-2 used for COVID-19 treatment in animal models

The ongoing COVID-19 pandemic has continued to affect millions of lives worldwide, leading to the urgent need for novel therapeutic strategies. G-quadruplexes (G4s) have been demonstrated to regulate life cycle of multiple viruses. Here, we identify several highly conservative and stable G4s in SARS-CoV-2 and clarify their dual-function of inhibition of the viral replication and translation processes. Furthermore, the cationic porphyrin compound 5,10,15,20-tetrakis-(N-methyl-4-pyridyl)porphine (TMPyP4) targeting SARS-CoV-2 G4s shows excellent antiviral activity, while its N-methyl-2-pyridyl positional isomer TMPyP2 with low affinity for G4 has no effects on SARS-CoV-2 infection, suggesting that the antiviral activity of TMPyP4 attributes to targeting SARS-CoV-2 G4s. In the Syrian hamster and transgenic mouse models of SARS-CoV-2 infection, administration of TMPyP4 at nontoxic doses significantly suppresses SARS-CoV-2 infection, resulting in reduced viral loads and lung lesions. Worth to note, the anti-COVID-19 activity of TMPyP4 is more potent than remdesivir evidenced by both in vitro and in vivo studies. Our findings highlight SARS-CoV-2 G4s as a novel druggable target and the compelling potential of TMPyP4 for COVID-19 therapy. Different from the existing anti-SARS-CoV-2 therapeutic strategies, our work provides another alternative therapeutic tactic for SARS-CoV-2 infection focusing on targeting the secondary structures within SARS-CoV-2 genome, and would open a new avenue for design and synthesis of drug candidates with high selectivity toward the new targets.

Withania somnifera (L.) Dunal (Ashwagandha) for the possible therapeutics and clinical management of SARS-CoV-2 infection: Plant-based drug discovery and targeted therapy.

Coronavirus disease 2019 (COVID-19) pandemic has killed huge populations throughout the world and acts as a high-risk factor for elderly and young immune-suppressed patients. There is a critical need to build up secure, reliable, and efficient drugs against to the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. Bioactive compounds of Ashwagandha [Withania somnifera (L.) Dunal] may implicate as herbal medicine for the management and treatment of patients infected by SARS-CoV-2 infection. The aim of the current work is to update the knowledge of SARS-CoV-2 infection and information about the implication of various compounds of medicinal plant Withania somnifera with minimum side effects on the patients’ organs. The herbal medicine Withania somnifera has an excellent antiviral activity that could be implicated in the management and treatment of flu and flu-like diseases connected with SARS-CoV-2. The analysis was performed by systematically re-evaluating the published articles related to the infection of SARS-CoV-2 and the herbal medicine Withania somnifera. In the current review, we have provided the important information and data of various bioactive compounds of Withania somnifera such as Withanoside V, Withanone, Somniferine, and some other compounds, which can possibly help in the management and treatment of SARS-CoV-2 infection. Withania somnifera has proved its potential for maintaining immune homeostasis of the body, inflammation regulation, pro-inflammatory cytokines suppression, protection of multiple organs, anti-viral, anti-stress, and anti-hypertensive properties. Withanoside V has the potential to inhibit the main proteases (Mpro) of SARS-CoV-2. At present, synthetic adjuvant vaccines are used against COVID-19. Available information showed the antiviral activity in Withanoside V of Withania somnifera, which may explore as herbal medicine against to SARS-CoV-2 infection after standardization of parameters of drug development and formulation in near future.

Discovery of Novel α-Methylene-γ-Butyrolactone Derivatives Containing Vanillin Moieties as Antiviral and Antifungal Agents.

On the basis of the structure of nicotlactone A (L1), a series of novel α-methylene-γ-butyrolactone derivatives B1-B43 were designed and synthesized by structure simplification and active fragment replacement strategies, and their antiviral and antifungal activities were evaluated. The bioassay studies indicated that many target compounds possessed good to excellent antiviral activity against tobacco mosaic virus (TMV) and some of these compounds exhibited specific antifungal activities against Valsa mali and Fusarium graminearum. Compound B32 exhibited the best anti-TMV activity (inactivation effect, 88.9%; protection effect, 65.8%; curative effect, 52.8%) in vivo at 500 mg/L, which is significantly higher than that of commercial virucides ribavirin and ningnanmycin. The inhibition effect of compound B32 was also visualized by the inoculation test using green fluorescent protein (GFP)-labeled TMV. The preliminary antiviral mechanism of compound B32 was investigated. Transmission electron microscopy (TEM) showed that compound B32 could destroy the integrity of virus particles. Then, molecular docking and isothermal titration calorimetry (ITC) analysis further demonstrated that compound B32 exhibited a strong binding affinity to the TMV coat protein with a dissociation constant (Kd) of 3.06 μM, superior to ribavirin. Thus, we deduced that compound B32 may interfere with the self-assembly of TMV particles by binding TMV coat protein (CP). In addition, compound B28 showed good in vitro activity against F. graminearum with an inhibition rate of 90.9% at 50 mg/L, which was greater than that of fluxapyroxad (59.1%) but lower than that of the commercial fungicide carbendazim (96.8%). The present study provides support for the application of these α-methylene-γ-butyrolactone derivatives as novel antiviral and antifungal agents in crop protection.

Recent breakthroughs in the treatment of chronic hepatitis Delta.

Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolerability and modest results. The detailed knowledge of the HDV replication cycle and its interaction with HBV allowed the introduction of new drugs which are currently in phase II or III of experimentation. Basically, bulevirtide, to date the only one approved by EMA, inhibits the entry of the virus into the hepatocytes and hence its intrahepatic spread; lonafarnib inhibits the pharnesylation process of the L-HDAg, which is critical for the assembly of the HDV virion; the nucleic acid polymers (NAPs) mainly block the production/release of HBsAg. The available clinical trials with these compounds showed an excellent anti-viral activity against HDV.

Why is the SARS-CoV-2 Omicron variant milder?

Why is the SARS-CoV-2 Omicron variant milder?

Exploring molecular moieties on carbonized polymer dots from flavonoid glycosides with activity against enterovirus A71

In recent years, numerous reports have revealed that hesperetin (Hsp) and its glycoside form, hesperidin (Hsd), exhibit significant antioxidant, anti-inflammatory, antibacterial, and antiviral activities. However, high concentrations of Hsp or Hsd are required to achieve in vivo therapeutic efficacy, since the accompanying toxicity has limited their use practical applications. To enhance bioactivity while reducing the potential associated toxicity, we synthesized carbonized polymer dots (CPDs) from hesperetin (Hsp) or hesperidin (Hsd) via mild pyrolysis and compared their antiviral activities with those of their raw precursors against enterovirus A71 (EV-A71). Our results showed that while Hsp and Hsd exhibited limited antiviral activity to suppress EV-A71-induced cytotoxicity in rhabdomyosarcoma cells, the CPDs possessed excellent antiviral activity with median effective concentration values of 44.2 and 17.7 μg mL−1, respectively, demonstrating improved antiviral effects compared to Hsp and Hsd (each >200 μg mL−1). Hsd-CPDs showed superior inhibition of EV-A71 infection compared to Hsp-CPDs, as shown by the >8-fold higher selectivity index. Molecular docking further suggests that apocynin and guaiacol moieties on the surface of the Hsd-CPDs could bind to the hydrophobic pocket of viral protein 1 of EV-A71, thus inhibiting viral attachment. We also demonstrated that Hsd-CPDs exert multiple mechanisms, including blocking viral entry and suppressing oxidative stress that triggered viral replication and translation. More importantly, Hsd-CPDs substantially alleviate the clinical symptoms and reduce death rates associated with EV-A71 infection in neonatal mice. Our results reveal the superior therapeutic effects of Hsd-CPDs against EV-A71 could be a potential antiviral agent worthy of future clinical investigation.

Treponema primitia α1-2-fucosyltransferase-catalyzed one-pot multienzyme synthesis of fucosylated oligosaccharide lacto-N-fucopentaose I with antiviral activity against enterovirus 71.

Fucosylated oligosaccharides have important biological functions as well as an excellent antiviral activity. A novel α 1-2-fucosyltransferase (α 2FT) from Treponema primitia (Tp2FT) was cloned and expressed in Escherichia coli BL21(DE3) and purified as an N-His6-tagged fusion protein (His6-Tp2FT). Mass spectrometry was carried out to identify the products of enzymatic reaction. The Tp2FT exhibited strict acceptor substrate specificity for type 1 structure (Galβ1-3GlcNAc)-containing glycans. It might be a promising emzyme for the chemo-enzymatic synthesis of lacto-N-fucopentaose I (LNFP I), which is one of the important fucosylated oligosaccharides. In this study, different in vitro experiments were used to study the biological activities of LNFP I. It could reduce the concentrations of inflammatory cytokines and effectively inhibit the synthesis of enterovirus 71 proliferation. LNFP I was an inhibitor of enterovirus 71 in the early stages of infection, it can used ininfant nutrition and might provide a new drug for hand foot mouth disease.

Ferulic acid derivatives with piperazine moiety as potential antiviral agents.

Plant virus diseases are difficult to control and severely threaten the productivity of crops, which leads to huge financial losses. To discover the new antiviral drugs, 34 novel ferulic acid derivatives with piperazine moiety were synthesized, and the antiviral activities were systematically screened as well. Bioassay results indicated that most of the target compounds had outstanding antiviral activities against tobacco mosaic virus (TMV) and cucumber mosaic virus (CMV) in vivo. In particular, compound E2 exhibited remarkable curative activities to TMV and CMV with EC50 values of 189.0 and 401.7μg/mL compared to those for ningnanmycin (387.0, 519.3μg/mL) and ribavirin (542.1, 721.5μg/mL). And then the mechanisms of compound E2 were studied by chlorophyll content, differentially expressed proteins and genes tests. The excellent antiviral activity of compound E2 was closely associated with the increase in host photosynthesis, which was confirmed by chlorophyll content, differentially expressed proteins and genes assays. Compound E2 can be considered as a lead structure for the discovery of new antiviral agents. © 2022 Society of Chemical Industry.

Continuously active disinfectant inactivates severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and human coronavirus 229E two days after the disinfectant was applied and following wear exposures.

The surface environment in rooms of coronavirus disease 2019 (COVID-19) patients may be persistently contaminated despite disinfection. A continuously active disinfectant demonstrated excellent sustained antiviral activity following a 48-hour period of wear and abrasion exposures with reinoculations. Reductions of >4-log10 were achieved within a 1-minute contact time for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) and the human coronavirus, 229E.

Discovery of novel thiophene derivatives as potent neuraminidase inhibitors.

Neuraminidase (NA) is an important target for the treatment of influenza. In this study, a new lead NA inhibitor, 4 (ZINC01121127), was discovered by pharmacophore-based virtual screening and molecular dynamic (MD) simulation. Some novel NA inhibitors containing thiophene ring were synthesized by optimizing the skeleton of the lead compound 4. Compound 4b had the most potent inhibitory activity against NA (IC50=0.03μM), which was better than the positive control oseltamivir carboxylate (IC50=0.06μM). 4b (EC50=1.59μM) also exhibits excellent antiviral activity against A/chicken/Hubei/327/2004 (H5N1-DW), which is superior to the reference drug OSC (EC50=5.97μM). Molecular docking study shows that the thiophene moiety plays an essential role in compound 4b, which can bind well to the active site of NA. The good activity of 4b may be also ascribed to the extending of quinoline ring into the 150-cavity. The results of this study may provide an insightful help for the development of new NA inhibitors.

Discovery of glyantrypine-family alkaloids as novel antiviral and antiphytopathogenic-fungus agents.

Plant diseases caused by viruses and fungi have caused great losses to crop quality and yield. The discovery of novel and efficient antiviral and antiphytopathogenic-fungus agents is urgently needed. It is the most important pesticide innovation strategy to find active compounds from natural products. Here, glyantrypine-family alkaloids were taken as the parent structures and a series of their derivatives were designed through molecular splicing, ring expansion, and ring contraction strategies, and synthesized. The anti-tobacco mosaic virus (TMV) activities and antifungal activities of these alkaloids were systematically investigated for the first time. The antiviral activities of compounds 7bb, 7bc, 11c, 18b, 18d, 28d, and 28e are equivalent to or better than that of ribavirin (inhibitory rates 39%, 37%, and 40% at 500 μg mL-1 for inactivation, curative, and protection activity in vivo, respectively). Compounds 18d and 28d with good antiviral activities were selected for antiviral mode of action studies, which indicated that these alkaloids could achieve good antiviral effects by inhibiting TMV particle extension during assembly. These compounds also exhibited broad-spectrum fungicidal activities. Glyantrypine-family alkaloids and their derivatives were synthesized and evaluated for anti-TMV and fungicidal activities for the first time. Compounds 18d and 28d with excellent antiviral activities and compound 7bc with remarkable fungicidal activity emerged as novel lead compounds. This study lays a foundation for the application of glyantrypine alkaloids in plant protection.

Design, Synthesis, and Mechanism of Antiviral Acylurea Derivatives Containing a Trifluoromethylpyridine Moiety.

Novel acylurea derivatives 7a-7ab were designed and synthesized by linking the active substructures trifluoromethylpyridine and anthranilic diamide via an acylurea bridge. Most of the title compounds exhibited good activity against tobacco mosaic virus (TMV), particularly compound 7x (EC50 of 211.8 μg/mL), which showed much higher curative activity than ningnanmycin (EC50 of 389.8 μg/mL), and compound 7ab, which showed excellent inactivation activity (EC50 of 36.1 μg/mL), similar to ningnanmycin (EC50 of 23.2 μg/mL). The preliminary mechanism of these derivatives was investigated. Autodocking analysis revealed that compounds 7x and 7ab had good affinity for TMV coat protein (TMV CP), with low binding energies (-7.86 and -8.59 kcal/mol) comparable to ningnanmycin (-8.75 kcal/mol). Molecular dynamics simulation showed that compound 7x had a stable system structure with a better binding free energy (-32.94 kcal/mol) than ningnanmycin (-25.62 kcal/mol). Microscale thermophoresis showed that compound 7x bound more strongly to TMV CP (Kd of 19.8 ± 7.3 μM) than ningnanmycin (Kd of 21.2 ± 7.3 μM). Transmission electron microscopy and self-assembly experiments demonstrated that compounds 7x and 7ab significantly obstructed the self-assembly of TMV RNA and TMV CP. This new acylurea derivative has excellent antiviral activity by targeting TMV CP and inhibiting TMV self-assembly and can be considered a candidate for antiviral applications.

Tailoring Nanonets‐Engineered Superflexible Nanofibrous Aerogels with Hierarchical Cage‐Like Architecture Enables Renewable Antimicrobial Air Filtration

AbstractPurification of pathogenic air has become an essential part of infection prevention and control. Most present air filters can hardly achieve excellent air filtration performance and the effective inactivation of the airborne pathogens at the same time. Herein, a bottom‐up approach is reported upon to construct cage‐like structured superflexible nanofibrous aerogels (CSAs) with renewable antimicrobial properties by combining electrospun silica nanofibers, bacterial cellulose nanofibers, and the hydrophobic SiOSi elastic binder. The following efficient grafting of N‐halamine compounds endows the CSAs with biocidal function. The resultant aerogels exhibit intriguing features of high porosity, hydrophobicity, superelasticity, foldability, renewable chlorination ability (>5400 ppm), high filtration performance toward PM0.3 (>99.97%, 189 Pa), and excellent antibacterial and antiviral activity (6 logs reduction within 5 min contact), enabling the aerogels to intercept and inactivate the pathogenic contaminants in air. The successful synthesis of CSAs provides a new possibility to design high‐performance air filtration materials for public health protection.

Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants.

The three pan-genotypic HCV NS3/4A protease inhibitors (PIs) currently in clinical use-grazoprevir, glecaprevir, and voxilaprevir-are quinoxaline-based P2-P4 macrocycles and thus exhibit similar resistance profiles. Using our quinoxaline-based P1-P3 macrocyclic lead compounds as an alternative chemical scaffold, we explored structure-activity relationships (SARs) at the P2 and P4 positions to develop pan-genotypic PIs that avoid drug resistance. A structure-guided strategy was used to design and synthesize two series of compounds with different P2 quinoxalines in combination with diverse P4 groups of varying sizes and shapes, with and without fluorine substitutions. Our SAR data and cocrystal structures revealed the interplay between the P2 and P4 groups, which influenced inhibitor binding and the overall resistance profile. Optimizing inhibitor interactions in the S4 pocket led to PIs with excellent antiviral activity against clinically relevant PI-resistant HCV variants and genotype 3, providing potential pan-genotypic inhibitors with improved resistance profiles.

Antiviral Activity of a Continuously Active Disinfectant Against the Human Coronavirus 229E

BackgroundBackground: Contaminated hospital room environmental surfaces and noncritical medical devices are a potential source of transmission of healthcare pathogens including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Technologies that provide continuous decontamination between episodes of manual cleaning and disinfection could reduce the risk for transmission of SARS-CoV-2 from surfaces in rooms of coronavirus disease (COVID-19) patients. The aim of this study was to evaluate a continuously active disinfectant (CAD) that is registered by the Environmental Protection Agency (EPA) to kill microbes (including viruses) on surfaces for >24 hours.MethodsMethods: We investigated the CAD against the human coronavirus, 229E, using the EPA “Protocol for Residual Self-Sanitizing Activity of Dried Chemical Residuals on Hard, Non-Porous Surfaces”. The method simulates contact and touches by incorporating “wear” of the test surface as well as re-inoculations of the test and control surfaces over at least 24 hours. The test surfaces were inoculated with ≥5-log10 per carrier, treated with the novel disinfectant, allowed to dry, and then abraded using a standardized abrasion machine under multiple alternating wet and dry wiping conditions (6 dry cycles, 6 wet cycles, total 12 cycles [2 passes per cycle=24 passes] each 24 hours) interspersed with 6 re-inoculations (or 12 re-inoculations in 48 hours) with ≥3.75-log10 of the test pathogen. After 24 or 48 hours, the surface was reinoculated with ≥5-log10 a final time, and the ability of the CAD to kill >99.9% of 229E with 1- or 5-minute contact times was measured on glass.ResultsResults: The CAD studied demonstrated excellent sustained antiviral activity (>4.0-log10 reduction) against 229E with 1- and 5-minute contact times after 24 and 48 hours.ConclusionsConclusion: Based on our data using 229E, CAD may reduce or eliminate the role of contaminated environmental surfaces and noncritical equipment in transmission of SARS-CoV-2.